Latest News

For the first time, clinical trial results show Ebola drugs improve survival rates

A clinical trial has shown that two therapies made from antibodies harvested from Ebola survivors appear to be improving survival rates among people who receive them, the World Health Organization and the National Institutes of Health announced Monday.

The therapies are a cocktail of three monoclonal Ebola antibodies made by Regeneron Pharmaceuticals and a single monoclonal antibody developed by the National Institute of Allergy and Infectious Diseases, part of the NIH. Regeneron’s cocktail is known as REGN-EB3; the single monoclonal antibody is known as mAb114.

Read the rest…

Source link

Related posts

Improving health insurance literacy aids Missourians' ACA enrollment


Traumatic brain injuries raise risk of psychiatric ills in soldiers


7 Benefits Coconut Oil Can Give To Hair And Scalp


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy